Clinical Trial Update: Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating ultra-short glucocorticoids with tocilizumab for giant cell arteritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Tocilizumab (tocilizumab)
• ultra-short glucocorticoids

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Giant Cell Arteritis | Phase 1, Phase 2 | Status: COMPLETED